[Pseudofolliculitis barbae].
Ribera
M
M
Servicio de Dermatología, Hospital Universitari de Sabadell, Corporació Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Barcelona, España. miquel.ribera@uab.cat
Fernández-Chico
N
N
Casals
M
M
D001585:Benzoyl Peroxide / Q000627:therapeutic use; D044383:Black People; D002921:Cicatrix / Q000209:etiology / Q000517:prevention & control; D003131:Combined Modality Therapy; D003879:Dermatologic Agents / Q000627:therapeutic use; D004198:Disease Susceptibility; D000518:Eflornithine / Q000627:therapeutic use; D005148:Facial Dermatoses / Q000188:drug therapy / Q000208:ethnology / Q000209:etiology* / Q000532:radiotherapy; D005260:Female; D005499:Folliculitis / Q000188:drug therapy / Q000208:ethnology / Q000209:etiology / Q000532:radiotherapy; D006201:Hair Diseases / Q000188:drug therapy / Q000208:ethnology / Q000209:etiology* / Q000532:radiotherapy; D006204:Hair Removal / Q000009:adverse effects* / Q000295:instrumentation / Q000379:methods; D006628:Hirsutism / Q000150:complications; D006801:Humans; D017495:Hyperpigmentation / Q000209:etiology / Q000517:prevention & control; D007627:Keloid / Q000209:etiology / Q000517:prevention & control; D054025:Lasers, Dye / Q000627:therapeutic use; D028022:Low-Level Light Therapy; D008297:Male; D012880:Skin Pigmentation; D044465:White People
D003879:Dermatologic Agents; D001585:Benzoyl Peroxide; D000518:Eflornithine
Pseudofoliculitis de la barba.